Stem cell therapy along with clinical application

Reading File

Stem cell therapy uses undifferentiated cells that can self-renew and develop into specialized cell types. Its aim is to replace, repair, or modulate damaged tissue, although many proposed uses remain experimental.

Topic map

Basic concepts: potency, self-renewal, differentiation, stem-cell niche
Types of stem cells: embryonic, adult/somatic, induced pluripotent stem cells, perinatal sources
Sources and harvesting: bone marrow, peripheral blood, cord blood, adipose tissue
Processing and transplantation: autologous vs allogeneic therapy, conditioning, engraftment
Established clinical applications
- Hematopoietic stem-cell transplantation for blood cancers and marrow failure
- Selected inherited immunodeficiency and metabolic diseases
- Corneal/limbal stem-cell transplantation for ocular-surface disease
- Skin epithelial stem-cell grafting in severe burns
Emerging or investigational applications: neurological disorders, heart disease, diabetes, cartilage/bone repair, liver disease, spinal-cord injury
Risks and limitations: graft-versus-host disease, rejection, infection, tumor formation, genetic instability, ethical and regulatory issues
Ethics and regulation: embryonic stem cells, informed consent, unproven commercial “stem-cell clinics”

High-level clinical perspective

The most established and widely used form is hematopoietic stem-cell transplantation (HSCT). Blood-forming stem cells from bone marrow, mobilized peripheral blood, or umbilical-cord blood can restore marrow function after chemotherapy or replace defective hematopoiesis in selected diseases.

For many non-blood conditions, stem-cell treatment is still under clinical investigation. Claims that injections of “stem cells” cure arthritis, autism, paralysis, dementia, diabetes, or aging should be treated cautiously unless supported by regulated clinical-trial evidence. Potential harms include infection, immune complications, thrombosis, inappropriate tissue growth, and malignancy.

Which section would you like developed into detailed study notes?

Clinical application based on system wise

Reading File

Stem-cell therapy: clinical applications by body system

Hematologic and immune system
- Hematopoietic stem-cell transplantation (HSCT)
- Leukemia, lymphoma, multiple myeloma
- Aplastic anemia, thalassemia, sickle-cell disease
- Primary immunodeficiency and selected inherited metabolic disorders
Cardiovascular system
- Ischemic heart disease and myocardial infarction
- Heart failure
- Vascular ischemia and peripheral arterial disease
  Mostly investigational, with no routine regenerative stem-cell treatment established.
Nervous system
- Spinal-cord injury
- Stroke
- Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis
- Retinal and optic-nerve disorders
  Predominantly research or regulated clinical-trial use.
Endocrine and metabolic system
- Type 1 diabetes: pancreatic islet or stem-cell-derived insulin-producing cell replacement
- Diabetic foot ulcers
- Adrenal or thyroid regeneration
  Cell replacement for type 1 diabetes is an advancing but specialized field; most other uses remain experimental.
Musculoskeletal system
- Bone defects and non-union fractures
- Cartilage injury and osteoarthritis
- Tendon, ligament, and skeletal-muscle injury
- Osteonecrosis of femoral head
  Bone-marrow-derived cell procedures are used in selected settings, but many marketed orthopedic injections lack strong evidence.
Skin and burns
- Cultured epithelial autografts for extensive burns
- Chronic wounds, venous ulcers, pressure injury, diabetic ulcers
- Epidermolysis bullosa
  Skin grafting and epithelial-cell approaches have the clearest clinical role.
Ophthalmic system
- Limbal stem-cell deficiency after chemical burns or severe ocular-surface disease
- Corneal epithelial reconstruction
- Retinal pigment epithelium replacement in macular degeneration
  Limbal stem-cell transplantation is an established application; retinal therapies remain investigational.
Gastrointestinal and hepatobiliary system
- Liver failure, cirrhosis, inflammatory bowel disease
- Intestinal failure and fistulas in Crohn disease
- Pancreatic cell replacement
  Autologous HSCT can be considered in a small group with severe refractory Crohn disease in expert centers; other regenerative uses are investigational.
Respiratory system
- Acute respiratory distress syndrome
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- COVID-19-related lung injury
  No stem-cell therapy is standard treatment for these conditions outside approved research.
Renal and urinary system
- Acute kidney injury
- Chronic kidney disease
- Bladder reconstruction and stress urinary incontinence
  Experimental.
Reproductive system
- Premature ovarian insufficiency
- Endometrial regeneration in Asherman syndrome
- Male infertility
  Experimental and should only be offered within properly approved research protocols.
Dental and craniofacial system
- Periodontal regeneration
- Alveolar bone regeneration
- Pulp and dentin regeneration
- Jaw defects
  Mainly experimental or limited specialized regenerative procedures.

Core clinical message

The best-established clinical use is transplantation of hematopoietic stem cells to restore the blood and immune system. Established localized applications include limbal stem-cell transplantation for certain ocular-surface disorders and cultured epithelial grafts for major burns. In most other systems, stem-cell therapy is investigational and requires controlled trials, appropriate regulatory approval, long-term follow-up, and transparent discussion of risks such as infection, immune reaction, graft-versus-host disease, thrombosis, abnormal tissue formation, and tumors.

Which system should I expand into detailed exam notes first?

Genetic modelling 10 marks answer

Reading File

Finding Sources

Searching PubMed

"disease modeling" AND "induced pluripotent stem cells"

Searching the Web

genetic disease modelling induced pluripotent stem cells genome editing clinical applications review

Genetic Modelling Using Stem Cells

Genetic modelling is the creation of laboratory models of human genetic disease by using patient-derived cells, induced pluripotent stem cells (iPSCs), genome-editing methods, and organoids. It helps study how a mutation produces disease and permits testing of treatments in genetically relevant human cells.

Principle

Somatic cells such as skin fibroblasts or blood cells are obtained from a patient with a known mutation. These cells are reprogrammed into iPSCs, which can differentiate into disease-relevant cells, for example neurons, cardiomyocytes, hepatocytes, or retinal cells. The resulting cells retain the patient's genetic mutation and can reproduce important disease features in vitro.

Steps in genetic modelling

Identify the disease-causing mutation by genetic testing.
Collect patient cells, commonly blood cells or skin fibroblasts.
Reprogram cells to iPSCs using transcription factors.
Differentiate iPSCs into the target cell type affected by disease.
Study phenotype, such as altered cell structure, metabolism, electrical activity, protein expression, or drug response.
Use CRISPR-Cas9 or other gene-editing tools to:
- Introduce a mutation into normal cells.
- Correct the mutation in patient-derived iPSCs.
Compare mutant, corrected, and normal control cells. A corrected line is termed an isogenic control, since it differs mainly at the targeted mutation.
Screen drugs and evaluate possible gene or cell therapies.

Applications

System	Examples of genetic modelling
Nervous system	Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, spinal muscular atrophy, epilepsy, autism spectrum disorders
Cardiovascular system	Long-QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic and dilated cardiomyopathy
Hematologic system	Sickle-cell disease, thalassemia, Fanconi anemia, inherited bone-marrow failure syndromes
Metabolic and liver disease	Alpha-1 antitrypsin deficiency, glycogen-storage diseases, familial hypercholesterolemia, urea-cycle defects
Endocrine system	Monogenic diabetes and disorders of pancreatic beta cells
Respiratory system	Cystic fibrosis, alpha-1 antitrypsin deficiency, genetic interstitial lung diseases
Kidney disease	Polycystic kidney disease, Alport syndrome, inherited tubular disorders
Eye disorders	Retinitis pigmentosa, Stargardt disease, inherited retinal degeneration
Skin disorders	Epidermolysis bullosa, ichthyosis, pigmentary disorders

Clinical significance

Explains the genotype-phenotype relationship.
Identifies disease mechanisms and new molecular targets.
Enables patient-specific drug screening and prediction of toxicity.
Supports precision medicine, as different patients may respond differently to the same drug.
Helps test gene correction before clinical use.
May reduce dependence on animal models, which often do not reproduce human disease accurately.

Limitations

iPSC-derived cells may be immature and may not fully replicate adult disease.
Reprogramming can introduce epigenetic and genetic variation.
Complex polygenic diseases and environmental influences are difficult to model.
CRISPR editing can cause off-target changes.
Organoid models lack full blood supply, immune interactions, and whole-body physiology.
Ethical, cost, biosafety, and regulatory issues remain.

Conclusion

Genetic modelling with patient-specific iPSCs and genome editing is a major tool for studying inherited disease, discovering drugs, and developing individualized therapy. At present, its principal role is in research and preclinical drug development, while direct clinical application requires strict evidence of safety and efficacy. Genome editing enables mutation correction or introduction to establish isogenic control lines and validate whether a variant is truly disease-causing, as described in this review of iPSC genome editing.

This is a shared conversation. Sign in to Orris to start your own chat.